Competition from generic drugs is a critical way to reduce drug prices, with a generic typically costing 85 to 90 percent less than its brand-name equivalent. But consumers wait years longer than they should to see those savings when drug companies pay to delay competition.
WASHINGTON -- A change of heart from the Obama administration may pave the way to a groundbreaking global deal to provide lifesaving medications to de...
The case for drastically reducing and eventually abolishing medical patents is clear: they raise the social cost of drugs, and medicine, while providing little or even a negative incentive for medical innovation.